1. Home
  2. PCSA vs HTCR Comparison

PCSA vs HTCR Comparison

Compare PCSA & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.29

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$2.90

Market Cap

4.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
HTCR
Founded
2011
2009
Country
United States
Japan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.4M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
PCSA
HTCR
Price
$2.29
$2.90
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
49.4K
37.4K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
87.84%
EPS Growth
N/A
414.29
EPS
N/A
N/A
Revenue
$5,000.00
$30,407,229.00
Revenue This Year
N/A
$123.26
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.19
52 Week Low
$0.11
$0.15
52 Week High
$8.88
$3.97

Technical Indicators

Market Signals
Indicator
PCSA
HTCR
Relative Strength Index (RSI) 53.43 44.24
Support Level $1.92 $0.27
Resistance Level $2.47 $3.69
Average True Range (ATR) 0.22 0.28
MACD 0.05 -0.03
Stochastic Oscillator 78.38 5.36

Price Performance

Historical Comparison
PCSA
HTCR

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.

Share on Social Networks: